Kivorent News

Sunday, November 22, 2026

Health techExplainer

How Medicare decides whether to pay for a new medical device

An FDA clearance lets a company sell a device. Whether Medicare pays for it is a separate set of decisions on coverage, billing codes and payment rates, and each can take years.

Docket, covering health regulation and AI in care
, 4 min read

3separate Medicare questions: coverage, coding, payment

What to know

  • FDA marketing authorization and Medicare coverage are separate decisions made by separate agencies under different standards.
  • Most Medicare coverage decisions are made locally by regional contractors; national decisions from CMS are rarer and follow a set timeline.
  • A covered device still needs a billing code and a payment rate before a hospital or clinic is paid for using it.

A press release that says a device has been cleared by the Food and Drug Administration answers one question: may the company sell it in the United States? It does not answer the question that decides whether many hospitals buy it: will Medicare pay when it is used? That question belongs to a different agency, the Centers for Medicare & Medicaid Services (CMS), and it is really three questions, answered in different places and on different clocks.

Question one: is it covered?

The FDA asks whether a device is safe and effective, or substantially equivalent to one already on the market (see our explainer on clearance, approval and De Novo). Medicare asks something else. The Social Security Act lets it pay only for items and services that are "reasonable and necessary" to diagnose or treat illness or injury, and only if they fit one of the benefit categories Congress wrote into the law. A device can pass the FDA's test and fail Medicare's, usually because the evidence shows it works but not that it improves outcomes for Medicare's mostly older patients.

Coverage decisions come in two sizes:

  • Local coverage determinations (LCDs). Medicare Administrative Contractors, the private companies that process claims for each region, write most coverage policies. A device can be covered in one region and not another.
  • National coverage determinations (NCDs). CMS can decide coverage for the whole country. The process is set by statute: CMS posts a proposed decision, generally within six months of opening a review, takes 30 days of public comment, then issues a final decision within 60 days after comment closes.

Where no policy exists, contractors judge claims one at a time. That is legal but unpredictable, which is why companies often lobby for a written policy.

CMS can also cover a technology on the condition that patients are enrolled in a study or registry, called coverage with evidence development. It is the agency's way of saying yes while the evidence is still coming in.

Question two: is there a code?

Claims are billed with codes. Procedures that physicians perform use CPT codes, which the American Medical Association's CPT Editorial Panel maintains. New technologies often start with a Category III code, a temporary tracking code that usually has no set national payment, before earning a permanent Category I code once use and evidence grow. Supplies and equipment use HCPCS Level II codes, which CMS assigns. Without a code that describes the service, a provider has no clean way to bill for it, coverage or not.

Question three: how much does it pay?

Rates depend on where care happens. Physicians are paid under the physician fee schedule, which CMS updates every year by rule; our story on the 2027 fee schedule shows how those yearly changes move rates for remote monitoring. Hospital outpatient departments are paid under a separate system that can give a new device temporary "pass-through" payments on top of the usual rate. For inpatient stays, a new technology add-on payment covers part of the extra cost of a new device for a few years while CMS gathers data. Both temporary payments have an easier route for devices with FDA breakthrough designation.

The faster lane, and the one that closed

In 2021 CMS finalized a rule that would have given breakthrough devices four years of automatic national coverage the moment the FDA authorized them. It repealed that rule later the same year, citing concern that coverage would not depend on evidence for Medicare patients.

The replacement, Transitional Coverage for Emerging Technologies (TCET), was finalized in August 2024. It is narrower: CMS accepts up to five breakthrough-designated devices a year into a process that starts working with the company before FDA authorization, aiming for a national coverage decision within about six months after the device reaches the market. Diagnostic lab tests are not eligible.

Where software and AI fit

Software has had the hardest time fitting the benefit categories, because many were written for physical equipment and clinician services. Paths have opened piece by piece: remote monitoring codes for connected home devices (our explainer), new codes for FDA-cleared digital mental health treatment devices added in the 2025 fee schedule, and individual CPT codes and add-on payments for specific AI tools in imaging and eye care. There is still no general Medicare payment for "AI" as such. Each tool needs its own route through the three questions. Each of those changes arrives through the rulemaking process described in our explainer on how federal health rules become final.

Medicare Advantage plans must cover what traditional Medicare covers, but they can add their own rules such as prior authorization.

Why it matters

When a health tech company announces an FDA clearance, the next questions are whether Medicare covers the device, whether a code exists to bill for it, and what that code pays. A clearance with no answer to those three is a permission to sell, not a market. Reading coverage news the same way, and noting whether a decision is local, national or conditional on a study, tells you how far a new device has actually come.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Digital health and AI in careFDA and health regulationAI law and policy

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.